The ongoing decline in share price and lack of revenue growt...
The ongoing decline in share price and lack of revenue growth could discourage potential investors. Despite this, some might see the recent sell-off as an opportunity should there be signs of a long-term growth trend.
Denali Therapeutics (NASDAQ:DNLI Investor Three-year Losses Grow to 56% as the Stock Sheds US$334m This Past Week
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment